Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

類似資料

• Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
  著者:: Tore K Kvien, 等
  出版事項: (2019-05-01)
• Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
  著者:: Vivian P. Bykerk, 等
  出版事項: (2023-02-01)
• Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
  著者:: Jeffrey R. Curtis, 等
  出版事項: (2017-12-01)
• Certolizumab pegol in the treatment of spondyloarthritis
  著者:: Mariusz Korkosz
  出版事項: (2014-09-01)
• CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
  著者:: Sh. F. Erdes
  出版事項: (2016-02-01)